Latest Breaking News On - Modulator platform - Page 1 : comparemela.com

QurAlis to Present Data That Show TDP-43 Pathology Drives Loss of Synaptic UNC13A Function in Neurodegenerative Diseases Including ALS and Frontotemporal Dementia

/PRNewswire/ QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that will alter.

United kingdomSandy hinckleyQurali asosInternational symposiumPrnewswire quralis corporationAlis corporationMis splicing drives synaptic dysfunctionCell biologySplice modulator platformModulator platform

QurAlis to Present Data Showing Link Between TDP-43 Pathology and Role of UNC13A in Neuronal Biology Related to ALS and Other Neurodegenerative Diseases

QurAlis to Present Data Showing Link Between TDP-43 Pathology and Role of UNC13A in Neuronal Biology Related to ALS and Other Neurodegenerative Diseases
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomDaniel elbaumQuralis corporationHarvard medical schoolPrnewswire quralis corporationHarvard universityAlis corporationBiennial conferenceSplice modulator platformModulator platform

QurAlis FlexASOs Show High Potency and Improved Safety Over Standard ASOs

QurAlis FlexASOs Show High Potency and Improved Safety Over Standard ASOs
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHarvard universityUnited kingdomQurali flexDaniel elbaumQurali flexasosKasper roetKevin egganCompany flexQuralis corporationEggan labHarvard medical schoolPrnewswire quralis corporationDevelopment of splice switching oligonucleotidesSplice modulator platformAnnual oligonucleotides

QurAlis Reveals Newest Program Targeting UNC13A RNA Mis-splicing Incorporating its FlexASO™ Platform

/PRNewswire/ QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS).

United kingdomAngela gengeKasper roetKathy vincentMuscular dystrophy associationHarvard universityQuralis corporationHarvard medical schoolScientific congressPrnewswire quralis corporationSplice modulator platformAlis corporationDystrophy associationDirected therapyGene therapyModulator platform